Abstract 5914
Background
The case for investing in better integrated mental health provision and training in cancer care is compelling. Mental health co-morbidity in cancer and end of life care is very common, poorly recognized, and leads to distress and loss of functioning. The recent SMaRT oncology trials, (Walker et al., 2014) have demonstrated that up to 73% of cancer patients with depression receive no evidence-based treatment for their depression. Standardized mortality ratio (SMR) for completed suicide in the cancer patient is four to seven times that of the matched population, (Robinson et al., 2009; Robson et al ., 2010). The increased awareness of co-morbid mental health conditions have impacted upon and influenced the cancer world. Yet, despite the plethora of research and policy advocating for better mental health provision for cancer patients, there is still a lack of recognition of the importance of assessing and managing co-morbid mental health in cancer patients.
Methods
The authors designed a one-day simulation based training programme using trained actors portraying cancer journeys, from diagnosis to end of life, with a number of different and relevant mental health co-morbidities. Inter-professional participants (n = 75) filled questionnaires both before and after the intervention (the simulation programme). The questionnaires consisted of multiple choice questions assessing knowledge of mental health co-morbidity in the cancer patient, and confidence (self- rated 1-5 Likert scales).
Results
Statistical t test analysis of pre v post intervention scores (n = 75) revealed highly statistically significant imrpovements to participants’ clinical knowledge (p < 0.0001) and confidence (p < 0.0001) as a result of the simulation intervention.
Conclusions
This study demonstrates that an innovative simulation programme has been evaluated as highly effective in improving knowledge and confidence of inter-professional learners at managing mental health co-morbidity in cancer patients. More research in this educational modality is welcomed in training clinicians.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
A. Fernando.
Funding
Health Education England.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3409 - Effect and safety of immune checkpoint inhibitors for brain metastases from non-small cell lung cancer
Presenter: Toshihiko Iuchi
Session: Poster Display session 1
Resources:
Abstract
3683 - Impact of Radiotherapy on efficacy of anti-programmed death 1 (PD-1) antibodies in metastatic NSCLC
Presenter: Evangeline Samuel
Session: Poster Display session 1
Resources:
Abstract
3924 - Pembrolizumab frontline monotherapy in patients with NSCLC and high PD-L1 expression: Real World Data from a European Cohort with focus on subgroups of interest
Presenter: Giannis Mountzios
Session: Poster Display session 1
Resources:
Abstract
3970 - Patients with metastatic non-small cell lung cancer and PD-L1 expression in Germany. Treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315)
Presenter: Martin Sebastian
Session: Poster Display session 1
Resources:
Abstract
5350 - The efficacy and safety of pembrolizumab as a first-line therapy in PD-L1 50% positive advanced NSCLC (HOPE-001)
Presenter: Motohiro Tamiya
Session: Poster Display session 1
Resources:
Abstract
3832 - Osimertinib in epidermal growth factor receptor (EGFR) T790M advanced non-small cell lung cancer (NSCLC): analysis of patients with central nervous system (CNS) metastases in a real-world study (ASTRIS)
Presenter: Giulio Metro
Session: Poster Display session 1
Resources:
Abstract
4082 - Real-world (RW) treatment patterns and outcomes for second-line (2L) therapy and beyond in patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC receiving a first-line (1L) first- or second-generation (1G/2G) EGFR tyrosine kinase inhibitor (TKI)
Presenter: Riyaz Shah
Session: Poster Display session 1
Resources:
Abstract
2855 - Impact of ramucirumab (RAM) + erlotinib (ERL) on EGFR mutations in circulating tumor DNA – The 1st report of a biomarker study in Japanese patients from RELAY: Global Ph3 study of ERL + RAM or placebo (PL) in 1L metastatic NSCLC with EGFR activating mutations
Presenter: Kazuto Nishio
Session: Poster Display session 1
Resources:
Abstract
2911 - Apatinib combined with EGFR - TKI in treating advanced non-small cell lung cancer with EGFR - TKI resistance
Presenter: Ruifen Tian
Session: Poster Display session 1
Resources:
Abstract
2100 - Updated analysis of a phase I trial of afatinib (Afa) and bevacizumab (Bev) in chemo-naïve patients (pts) with advanced non-small-cell lung cancer (NSCLC) harboring EGFR-mutations: OLCSG1404
Presenter: Takashi Ninomiya
Session: Poster Display session 1
Resources:
Abstract